Acute Effects of High-Intensity Interval and Moderate-Intensity Continuous Exercise on GLP-1, Appetite and Energy Intake in Obese Men: A Crossover Trial

Nutrients. 2018 Jul 12;10(7):889. doi: 10.3390/nu10070889.

Abstract

This study investigated the effect of high-intensity interval (HIIE) and moderate-intensity continuous exercise (MICE) on glucagon-like peptide 1 (GLP-1), appetite and energy intake (EI) in obese men. In a randomized crossover trial, 12 participants (28.4 ± 2.6 years, 35.5 ± 4.5 kg/m², 39.8 ± 2.2% body fat) performed: (I) Control (CON, no exercise); (II) MICE (20 min, 70% of maximal heart rate) and (III) HIIE (10 × 1 min at 90% of maximal heart rate with 1 min recovery). GLP-1 and appetite were assessed at: (I) PRE: pre-exercise; (II) POST: immediately post-exercise; (III) POST-1 h: 1 h post-exercise. EI was assessed after an ad libitum meal offered 1 h post-exercise and over 24 h. There was a significant time × condition interaction for GLP-1 (p = 0.035). Higher GLP-1 levels in MICE vs. CON (p = 0.024) and a trend for HIIE vs. CON (p = 0.069) POST-1h was found. Hunger was reduced immediately post-HIIE compared to CON (p < 0.01), but was not sustained POST-1 h (p > 0.05). EI did not differ between the sessions 1 h post-exercise or over 24H (p > 0.05). In summary, although MICE increased GLP-1 levels POST-1h and HIIE induced a transient reduction in hunger, both exercise protocols did not impact EI in obese men.

Keywords: T0; T30 and T90 min; compensation; energy intake; gastrointestinal hormones; high intensity interval exercise; hunger; obesity; respectively.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Appetite Regulation*
  • Biomarkers / blood
  • Brazil
  • Cross-Over Studies
  • Eating*
  • Energy Intake*
  • Exercise Therapy / methods*
  • Glucagon-Like Peptide 1 / blood*
  • High-Intensity Interval Training*
  • Humans
  • Hunger
  • Male
  • Obesity / blood
  • Obesity / physiopathology
  • Obesity / psychology
  • Obesity / therapy*
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Biomarkers
  • Glucagon-Like Peptide 1